Open access
Aug 2026
Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE)
Although abemaciclib tolerability and discontinuation rates align with trial data, dose reductions are substantially more frequent in routine practice and longer follow-up is needed to establish how these reductions affect overall efficacy.
H. Abdallah, Y. Owoseni, B. Baraka et al.
· ESMO real world data and dig... · 0 citations